Related Experiment Videos
[Tumor markers in malignant lymphoma]
1Dept. of Clinical Laboratory Medicine, Nagoya City University Medical School.
Gan to Kagaku Ryoho. Cancer & Chemotherapy
|January 31, 2002
Summary
Tumor markers aid in monitoring lymphoma treatment effectiveness and predicting patient outcomes. Specific markers like soluble interleukin-2 receptor and cyclin D1 expression offer valuable prognostic insights.
Area of Science:
- Oncology
- Hematology
- Biomarker Research
Context:
- Malignant lymphoma diagnosis and treatment.
- Role of tumor markers in clinical oncology.
- Prognostic factors in hematological malignancies.
Purpose:
- To review the clinical utility of tumor markers in malignant lymphoma.
- To differentiate between markers for therapeutic monitoring and prognostic assessment.
- To highlight specific markers and their implications.
Summary:
- Tumor markers are crucial for monitoring therapeutic effects and as prognostic factors in malignant lymphoma.
- Soluble interleukin-2 receptor (measured by ELISA) is used for therapeutic monitoring.
- Cellular markers detected by immunohistology and flow cytometry, such as cyclin D1 overexpression in mantle cell lymphoma, are significant prognostic indicators.
Impact:
- Improved patient management through accurate therapeutic monitoring.
- Enhanced prognostic stratification for personalized treatment strategies.
- Potential for earlier identification of high-risk lymphoma cases requiring intensive therapy.